CA2536936A1 - E- and k-coiled-coil fusion proteins comprising tgf-b cell receptor domains - Google Patents
E- and k-coiled-coil fusion proteins comprising tgf-b cell receptor domains Download PDFInfo
- Publication number
- CA2536936A1 CA2536936A1 CA002536936A CA2536936A CA2536936A1 CA 2536936 A1 CA2536936 A1 CA 2536936A1 CA 002536936 A CA002536936 A CA 002536936A CA 2536936 A CA2536936 A CA 2536936A CA 2536936 A1 CA2536936 A1 CA 2536936A1
- Authority
- CA
- Canada
- Prior art keywords
- coil
- coiled
- protein
- fusion protein
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract 29
- 108020001507 fusion proteins Proteins 0.000 title claims abstract 29
- 230000027455 binding Effects 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 239000003446 ligand Substances 0.000 claims abstract 8
- 239000000539 dimer Substances 0.000 claims abstract 7
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract 5
- 230000000694 effects Effects 0.000 claims abstract 5
- 102000020233 phosphotransferase Human genes 0.000 claims abstract 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 102000004169 proteins and genes Human genes 0.000 claims 22
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 230000001131 transforming effect Effects 0.000 claims 13
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 12
- 102000006240 membrane receptors Human genes 0.000 claims 12
- 102000005962 receptors Human genes 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 6
- 230000001086 cytosolic effect Effects 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims 2
- 229940116977 epidermal growth factor Drugs 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000893 fibroproliferative effect Effects 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000000833 heterodimer Substances 0.000 abstract 1
- 239000000710 homodimer Substances 0.000 abstract 1
- 230000036515 potency Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50085503P | 2003-09-05 | 2003-09-05 | |
| US60/500,855 | 2003-09-05 | ||
| PCT/CA2004/001616 WO2005024035A1 (en) | 2003-09-05 | 2004-09-02 | Coiled-coil fusion proteins comprising cell receptor domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2536936A1 true CA2536936A1 (en) | 2005-03-17 |
Family
ID=34273005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002536936A Abandoned CA2536936A1 (en) | 2003-09-05 | 2004-09-02 | E- and k-coiled-coil fusion proteins comprising tgf-b cell receptor domains |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1668133A4 (de) |
| JP (1) | JP2007503820A (de) |
| AU (1) | AU2004270774A1 (de) |
| CA (1) | CA2536936A1 (de) |
| WO (1) | WO2005024035A1 (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012071649A1 (en) * | 2010-11-29 | 2012-06-07 | National Research Council Of Canada | Covalently dimerized bivalent binding agents |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070184052A1 (en) * | 2003-05-09 | 2007-08-09 | Lin Herbert Y | Soluble tgf-b type III receptor fusion proteins |
| TWI386923B (zh) | 2004-03-18 | 2013-02-21 | Lg Electronics Inc | 其上具有區塊資訊之記錄媒體和用以形成、記錄及重製記錄媒體之設備和方法 |
| US7480764B2 (en) | 2004-03-18 | 2009-01-20 | Lg Electronics, Inc. | Recording medium with overlapping segment information thereon and apparatus and methods for forming, recording, and reproducing the recording medium |
| EP1735781B1 (de) | 2004-03-18 | 2013-07-17 | LG Electronics, Inc. | Vorrichtung und verfahren zur aufzeichnung und/oder wiedergabe von daten auf/vom aufzeichnungsmedium |
| EP2491391B1 (de) * | 2009-10-23 | 2018-02-28 | GE Healthcare Bio-Sciences AB | Verfahren zur bestimmung makromolekularer multimere |
| WO2018094173A1 (en) * | 2016-11-18 | 2018-05-24 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0854931A4 (de) * | 1995-10-06 | 2002-02-13 | Pence Inc | Methoden und zusammensetzungen für die detektion und reinigung von exprimierten proteinen über "coild coil heterodimer" wechselwirkungen |
| US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| AU2880800A (en) * | 1999-02-11 | 2000-08-29 | Xencor, Inc. | Structure-based screening techniques for drug discovery |
-
2004
- 2004-09-02 AU AU2004270774A patent/AU2004270774A1/en not_active Abandoned
- 2004-09-02 JP JP2006525014A patent/JP2007503820A/ja not_active Abandoned
- 2004-09-02 EP EP04761779A patent/EP1668133A4/de not_active Withdrawn
- 2004-09-02 WO PCT/CA2004/001616 patent/WO2005024035A1/en active Application Filing
- 2004-09-02 CA CA002536936A patent/CA2536936A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012071649A1 (en) * | 2010-11-29 | 2012-06-07 | National Research Council Of Canada | Covalently dimerized bivalent binding agents |
| US8987417B2 (en) | 2010-11-29 | 2015-03-24 | National Research Council Of Canada | Covalently dimerized bivalent binding agents |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1668133A4 (de) | 2007-08-29 |
| JP2007503820A (ja) | 2007-03-01 |
| AU2004270774A1 (en) | 2005-03-17 |
| WO2005024035A1 (en) | 2005-03-17 |
| EP1668133A1 (de) | 2006-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2890815B1 (de) | Verfahren zur diagnose und behandlung von krebs | |
| DeFazio et al. | Expression of c‐erbB receptors, heregulin and oestrogen receptor in human breast cell lines | |
| ES2426814T3 (es) | Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr | |
| Seki et al. | Pharmacological properties of TRK-820 on cloned μ-, δ-and κ-opioid receptors and nociceptin receptor | |
| JP2019518452A5 (de) | ||
| Valdenaire et al. | A new family of orphan G protein-coupled receptors predominantly expressed in the brain | |
| WO2015012397A1 (ja) | Ｎｔｒｋ３融合体の検出法 | |
| Pfeffer et al. | Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines | |
| Gilbertson et al. | Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma | |
| CA2536936A1 (en) | E- and k-coiled-coil fusion proteins comprising tgf-b cell receptor domains | |
| CA2706994A1 (en) | Use of eph-b4 and ephrin-a1 for predicting negative physiological response to the treatment with erythropoietin | |
| JP2012501164A5 (de) | ||
| ATE320489T1 (de) | Gfr-alpha3 und seine verwendungen | |
| Keller et al. | Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer | |
| WO2000023588B1 (en) | G-protein coupled receptors | |
| US20220281931A1 (en) | Chemically inducible polypeptide polymerization | |
| EP2099913A1 (de) | Vegfr-varianten und deren verwendung bei der diagnose und behandlung von mit schwangerschaft assoziierten medizinischen leiden | |
| Frankowski et al. | PLAIDD, a type II death domain protein that interacts with p75 neurotrophin receptor | |
| WO2001083551A1 (en) | Reagent for detection of biomolecules, and use thereof | |
| US20130131136A1 (en) | Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor | |
| Hayashi et al. | Identification and recombinant production of human laminin α4 subunit splice variants | |
| WO2009141440A1 (en) | Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma | |
| Ichikawa et al. | cDNA cloning and mRNA expression of estrogen receptor α in Japanese quail | |
| Lim et al. | Cloning and characterization of a bovine alpha interferon receptor | |
| Gripentrog et al. | Experimental evidence for lack of homodimerization of the G protein-coupled human N-formyl peptide receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20160111 |